Tyra Biosciences (TYRA) Competitors $10.35 +0.17 (+1.67%) As of 10:42 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TYRA vs. KNSA, VCEL, DNLI, CGON, VERA, GMTX, IMCR, GLPG, AGIO, and TWSTShould you be buying Tyra Biosciences stock or one of its competitors? The main competitors of Tyra Biosciences include Kiniksa Pharmaceuticals (KNSA), Vericel (VCEL), Denali Therapeutics (DNLI), CG Oncology (CGON), Vera Therapeutics (VERA), Gemini Therapeutics (GMTX), Immunocore (IMCR), Galapagos (GLPG), Agios Pharmaceuticals (AGIO), and Twist Bioscience (TWST). These companies are all part of the "pharmaceutical products" industry. Tyra Biosciences vs. Its Competitors Kiniksa Pharmaceuticals Vericel Denali Therapeutics CG Oncology Vera Therapeutics Gemini Therapeutics Immunocore Galapagos Agios Pharmaceuticals Twist Bioscience Kiniksa Pharmaceuticals (NASDAQ:KNSA) and Tyra Biosciences (NASDAQ:TYRA) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, community ranking, media sentiment and analyst recommendations. Does the media refer more to KNSA or TYRA? In the previous week, Kiniksa Pharmaceuticals had 23 more articles in the media than Tyra Biosciences. MarketBeat recorded 28 mentions for Kiniksa Pharmaceuticals and 5 mentions for Tyra Biosciences. Tyra Biosciences' average media sentiment score of 0.67 beat Kiniksa Pharmaceuticals' score of 0.25 indicating that Tyra Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kiniksa Pharmaceuticals 14 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Tyra Biosciences 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend KNSA or TYRA? Kiniksa Pharmaceuticals currently has a consensus target price of $38.80, indicating a potential upside of 29.94%. Tyra Biosciences has a consensus target price of $30.83, indicating a potential upside of 197.91%. Given Tyra Biosciences' higher possible upside, analysts clearly believe Tyra Biosciences is more favorable than Kiniksa Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kiniksa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Tyra Biosciences 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor KNSA or TYRA? Kiniksa Pharmaceuticals received 138 more outperform votes than Tyra Biosciences when rated by MarketBeat users. However, 77.08% of users gave Tyra Biosciences an outperform vote while only 65.30% of users gave Kiniksa Pharmaceuticals an outperform vote. CompanyUnderperformOutperformKiniksa PharmaceuticalsOutperform Votes17565.30% Underperform Votes9334.70% Tyra BiosciencesOutperform Votes3777.08% Underperform Votes1122.92% Which has better earnings & valuation, KNSA or TYRA? Kiniksa Pharmaceuticals has higher revenue and earnings than Tyra Biosciences. Kiniksa Pharmaceuticals is trading at a lower price-to-earnings ratio than Tyra Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKiniksa Pharmaceuticals$481.17M4.53$14.08M-$0.25-119.44Tyra BiosciencesN/AN/A-$69.13M-$1.63-6.35 Do institutionals and insiders believe in KNSA or TYRA? 54.0% of Kiniksa Pharmaceuticals shares are owned by institutional investors. Comparatively, 84.1% of Tyra Biosciences shares are owned by institutional investors. 54.6% of Kiniksa Pharmaceuticals shares are owned by company insiders. Comparatively, 15.2% of Tyra Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has more risk & volatility, KNSA or TYRA? Kiniksa Pharmaceuticals has a beta of 0.06, suggesting that its stock price is 94% less volatile than the S&P 500. Comparatively, Tyra Biosciences has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500. Is KNSA or TYRA more profitable? Tyra Biosciences has a net margin of 0.00% compared to Kiniksa Pharmaceuticals' net margin of -2.36%. Kiniksa Pharmaceuticals' return on equity of -7.31% beat Tyra Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Kiniksa Pharmaceuticals-2.36% -7.31% -5.95% Tyra Biosciences N/A -24.56%-23.31% SummaryKiniksa Pharmaceuticals and Tyra Biosciences tied by winning 8 of the 16 factors compared between the two stocks. Get Tyra Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for TYRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TYRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TYRA vs. The Competition Export to ExcelMetricTyra BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$549.48M$6.93B$5.60B$8.62BDividend YieldN/A2.55%5.28%4.18%P/E Ratio-6.438.8527.2320.02Price / SalesN/A256.44417.65154.33Price / CashN/A65.8538.2534.64Price / Book2.186.617.124.70Net Income-$69.13M$143.93M$3.23B$247.97M7 Day Performance1.77%3.84%2.74%2.64%1 Month Performance0.88%11.14%8.94%6.39%1 Year Performance-45.90%4.35%31.59%13.95% Tyra Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TYRATyra Biosciences2.0033 of 5 stars$10.35+1.7%$30.83+197.9%-49.7%$549.48MN/A-6.4320KNSAKiniksa Pharmaceuticals3.2592 of 5 stars$27.92+2.0%$38.80+39.0%+61.1%$2.04B$481.17M-199.41220Trending NewsInsider TradeVCELVericel2.6777 of 5 stars$40.46-2.0%$61.14+51.1%+2.0%$2.04B$238.54M674.45300Positive NewsHigh Trading VolumeDNLIDenali Therapeutics4.354 of 5 stars$13.96+5.4%$33.71+141.5%-29.7%$2.03B$330.53M-5.06430Positive NewsAnalyst RevisionHigh Trading VolumeCGONCG Oncology2.5187 of 5 stars$26.59+3.8%$58.22+119.0%-25.6%$2.03B$662K-17.6161Positive NewsAnalyst RevisionVERAVera Therapeutics2.9091 of 5 stars$31.74+67.5%$65.00+104.8%-42.5%$2.02BN/A-12.1640Short Interest ↑Analyst RevisionHigh Trading VolumeGMTXGemini TherapeuticsN/A$46.68-0.4%N/A+33.6%$2.02BN/A-46.6830High Trading VolumeIMCRImmunocore3.0627 of 5 stars$38.65+5.6%$58.89+52.4%-13.5%$1.94B$333.58M-40.68320Analyst RevisionHigh Trading VolumeGLPGGalapagos0.404 of 5 stars$29.20+1.5%$25.33-13.2%+8.2%$1.92B$288.19M0.001,310Positive NewsAGIOAgios Pharmaceuticals4.1274 of 5 stars$32.63+1.7%$56.00+71.6%-27.6%$1.89B$37.04M2.88390Positive NewsAnalyst RevisionTWSTTwist Bioscience4.2375 of 5 stars$31.07+6.0%$50.40+62.2%-31.9%$1.86B$347.68M-9.19990 Related Companies and Tools Related Companies KNSA Alternatives VCEL Alternatives DNLI Alternatives CGON Alternatives VERA Alternatives GMTX Alternatives IMCR Alternatives GLPG Alternatives AGIO Alternatives TWST Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TYRA) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tyra Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tyra Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TYRA Stock Free TYRA Stock Alerts